The regulatory status of palmitoylethanolamide, market by market.
This page is deliberately conservative. Where we can point to a public record we cite it; where we cannot, we say so rather than implying an approval that does not exist. Regulatory affairs teams tend to appreciate that more than optimism.
Read this first
Nothing on this page is regulatory advice, and PEAOID gives no warranty as to the status of palmitoylethanolamide in any territory. Positions change, and approvals are frequently specific to a named applicant, a named specification or a named product rather than to the ingredient in general. Confirm your own position with competent local counsel before you commit to a launch, a registration or a label.
PEAOID is FSSAI approved.
Palmitoylethanolamide does not currently appear in the ingredient schedules of the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use…) Regulations. Instead, it has been cleared repeatedly through the Food Safety and Standards (Approval for Non-Specified Food and Food Ingredients) Regulations — the mechanism India uses for ingredients that are not yet listed in a standard schedule.
PEAOID palmitoylethanolamide is FSSAI approved, with a valid Form II issued under the Food Safety and Standards (Approval for Non-Specified Food and Food Ingredients) Regulations — the mechanism India uses for ingredients not yet listed in a standard schedule. The Form II reference is provided in writing with our qualification pack.
Here is the part that matters commercially, and that most supplier websites gloss over: approvals under this route are granted to a named applicant, not to the ingredient. An approval held by one company is not a general clearance for every manufacturer, importer and trader. A supplier quoting a file number that belongs to somebody else is giving you nothing that will survive an audit. Ours is held in our own name, and we will show it to you.
The important nuance, which several supplier websites gloss over: these approvals are applicant-specific. An approval granted to one company is not automatically a general clearance for every manufacturer and importer. Any Indian business placing PEA on the domestic market should confirm its own position rather than relying on someone else's file number.
What this means for you
Buying from us. Material supplied by PEAOID is covered by our own Form II approval. Ask for the reference and we will provide it in writing with the qualification pack.
Selling in India. Your finished product still needs its own FSSAI licence and label compliance. Our approval covers the ingredient we supply; it does not extend to your finished good.
Checking anyone’s claim. Open the current status list at fssai.gov.in and search for palmitoylethanolamide and for palmitic acid mono-ethanolamide — entries appear under both names, which is why casual searches under-count. Then look at whose name is on it.
Position in the major export markets
| Market | Framework | Position as we read the public record | Confidence |
|---|---|---|---|
| India | FSSAI — NSF route | Approved, valid Form II held in our own name under the Non-Specified Food route. Applicant-specific by design, so a third party’s approval does not cover you. | Form II |
| Australia & New Zealand | TGA — listed medicines | Permitted as an active in listed medicines. Individual PEA products carry entries on the Australian Register of Therapeutic Goods. | Verified |
| Canada | Health Canada — NHP | Multiple licensed natural health products containing PEA hold NPNs and are on the market. | Verified |
| Italy | FSMP / food supplement | The most mature PEA market globally. Long-established as a food for special medical purposes; also permitted in food supplements. Most of the clinical literature originates here. | Well documented |
| United States | FDA — DSHEA | Marketed as a dietary-supplement ingredient. At least one supplier holds a self-affirmed GRAS dossier — a company determination, not an FDA approval. We have not been able to confirm an FDA-issued GRAS notice or a published NDI notification for PEA. | Partial |
| European Union | Novel food | No EU-wide novel food authorization has been confirmed. National positions differ, and several member states have PEA products on the market under their own frameworks. Treat this as a country-by-country question, not an EU one. | Check nationally |
| United Kingdom | FSA / novel food | No UK novel-food determination for palmitoylethanolamide located in the public record. | Unconfirmed |
| Middle East & South-East Asia | Various | Assessed case by case. Registration generally follows the Indian or Australian dossier. We supply the technical file needed for local registration. | Case by case |
Summary current as at July 2026 and based on publicly available records. “Verified” means we located the entry on the regulator's own published record; “partial” and “unconfirmed” mean exactly what they say.
The toxicology behind the ingredient
PEA has an unusually comfortable safety profile for a molecule with this much pharmacological activity — largely because it is endogenous, and because its metabolites are palmitic acid and ethanolamine, both of which the body already handles at scale.
- Developmental toxicity. A GLP-compliant OECD Test Guideline 414 study in pregnant rats at 250, 500 and 1,000 mg/kg/day established a NOAEL above 1,000 mg/kg/day for maternal toxicity, embryotoxicity, foetotoxicity and teratogenicity — the highest dose tested produced no adverse findings.1
- Clinical safety database. A review of 16 clinical trials covering roughly 1,590 patients concluded that, for courses up to 49 days, the pooled data exclude serious adverse reactions occurring at a rate of one in 200 or more.2
- Tolerability versus placebo. Pooled dropout across the randomized literature ran lower on PEA than on control — approximately 1.1% versus 4.3%.
- Reported adverse events. Mild and infrequent: gastrointestinal discomfort, transient drowsiness, headache, isolated reports of palpitations.
The limits of the safety data
Pregnancy and lactation. There are no human clinical data in pregnant or breastfeeding women. The rat developmental study is reassuring but it is animal data. Standard precautionary label wording is appropriate.
Long-term use. Most randomized trials run 8 to 12 weeks. Controlled data beyond twelve months does not exist in the public literature. The safety review that produced the one-in-200 figure explicitly declined to extend that conclusion past 60 days of treatment.
Interactions. No pharmacokinetic drug–drug interaction studies have been published. A theoretical interaction with fibrate PPAR-α agonists has been raised on mechanistic grounds but not demonstrated clinically.
What this means for a label
In practice, most markets treat PEA as a well-tolerated food ingredient with routine supplement cautions: not for pregnant or breastfeeding women, not for children without professional advice, consult a healthcare professional if on medication. Permitted claim language is a separate question and is jurisdiction-specific — we will share what other customers have used, but the claim is yours to substantiate.
References
- Deshmukh NS, Gumaste S, Subah S, Bogoda NO. Palmitoylethanolamide: prenatal developmental toxicity study in rats. International Journal of Toxicology 2021;40(2):161–170.
- Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol 2016. PMID 27220803
- Food Safety and Standards Authority of India, published status lists for applications under the Non-Specified Food and Food Ingredients Regulations. fssai.gov.in
- Therapeutic Goods Administration, Australian Register of Therapeutic Goods. tga.gov.au
Need the regulatory dossier for your market?
Tell us where you intend to sell. We will send the technical file, the toxicology summary and our reading of the local position — with the gaps marked as gaps.